317 related articles for article (PubMed ID: 28917578)
1. Emerging biomarkers for cancer immunotherapy in melanoma.
Axelrod ML; Johnson DB; Balko JM
Semin Cancer Biol; 2018 Oct; 52(Pt 2):207-215. PubMed ID: 28917578
[TBL] [Abstract][Full Text] [Related]
2. Biomarkers, measured during therapy, for response of melanoma patients to immune checkpoint inhibitors: a systematic review.
Ouwerkerk W; van den Berg M; van der Niet S; Limpens J; Luiten RM
Melanoma Res; 2019 Oct; 29(5):453-464. PubMed ID: 30855527
[TBL] [Abstract][Full Text] [Related]
3. Cutaneous melanoma and the immunotherapy revolution (Review).
Leonardi GC; Candido S; Falzone L; Spandidos DA; Libra M
Int J Oncol; 2020 Sep; 57(3):609-618. PubMed ID: 32582963
[TBL] [Abstract][Full Text] [Related]
4. Autoimmune genetic risk variants as germline biomarkers of response to melanoma immune-checkpoint inhibition.
Chat V; Ferguson R; Simpson D; Kazlow E; Lax R; Moran U; Pavlick A; Frederick D; Boland G; Sullivan R; Ribas A; Flaherty K; Osman I; Weber J; Kirchhoff T
Cancer Immunol Immunother; 2019 Jun; 68(6):897-905. PubMed ID: 30863922
[TBL] [Abstract][Full Text] [Related]
5. Emerging Tissue and Blood-Based Biomarkers that may Predict Response to Immune Checkpoint Inhibition.
Friedman CF; Postow MA
Curr Oncol Rep; 2016 Apr; 18(4):21. PubMed ID: 26922327
[TBL] [Abstract][Full Text] [Related]
6. Future perspectives in melanoma research : Meeting report from the "Melanoma Bridge". Napoli, December 1st-4th 2015.
Ascierto PA; Agarwala S; Botti G; Cesano A; Ciliberto G; Davies MA; Demaria S; Dummer R; Eggermont AM; Ferrone S; Fu YX; Gajewski TF; Garbe C; Huber V; Khleif S; Krauthammer M; Lo RS; Masucci G; Palmieri G; Postow M; Puzanov I; Silk A; Spranger S; Stroncek DF; Tarhini A; Taube JM; Testori A; Wang E; Wargo JA; Yee C; Zarour H; Zitvogel L; Fox BA; Mozzillo N; Marincola FM; Thurin M
J Transl Med; 2016 Nov; 14(1):313. PubMed ID: 27846884
[TBL] [Abstract][Full Text] [Related]
7. Novel Targets for the Treatment of Melanoma.
Ambrosi L; Khan S; Carvajal RD; Yang J
Curr Oncol Rep; 2019 Nov; 21(11):97. PubMed ID: 31696329
[TBL] [Abstract][Full Text] [Related]
8. Combining Immune Checkpoint Inhibitors: Established and Emerging Targets and Strategies to Improve Outcomes in Melanoma.
Khair DO; Bax HJ; Mele S; Crescioli S; Pellizzari G; Khiabany A; Nakamura M; Harris RJ; French E; Hoffmann RM; Williams IP; Cheung A; Thair B; Beales CT; Touizer E; Signell AW; Tasnova NL; Spicer JF; Josephs DH; Geh JL; MacKenzie Ross A; Healy C; Papa S; Lacy KE; Karagiannis SN
Front Immunol; 2019; 10():453. PubMed ID: 30941125
[TBL] [Abstract][Full Text] [Related]
9. Prognostic Biomarkers for Melanoma Immunotherapy.
Twitty CG; Huppert LA; Daud AI
Curr Oncol Rep; 2020 Feb; 22(3):25. PubMed ID: 32048065
[TBL] [Abstract][Full Text] [Related]
10. Role of immune checkpoint inhibitors in the revolutionization of advanced melanoma care.
Singh S; Numan A; Agrawal N; Tambuwala MM; Singh V; Kesharwani P
Int Immunopharmacol; 2020 Jun; 83():106417. PubMed ID: 32200155
[TBL] [Abstract][Full Text] [Related]
11. Immune checkpoint inhibitors for the treatment of melanoma.
Sabbatino F; Liguori L; Pepe S; Ferrone S
Expert Opin Biol Ther; 2022 May; 22(5):563-576. PubMed ID: 35130816
[TBL] [Abstract][Full Text] [Related]
12. Biomarkers for Response of Melanoma Patients to Immune Checkpoint Inhibitors: A Systematic Review.
Jessurun CAC; Vos JAM; Limpens J; Luiten RM
Front Oncol; 2017; 7():233. PubMed ID: 29034210
[TBL] [Abstract][Full Text] [Related]
13. Modern Aspects of Immunotherapy with Checkpoint Inhibitors in Melanoma.
Petrova V; Arkhypov I; Weber R; Groth C; Altevogt P; Utikal J; Umansky V
Int J Mol Sci; 2020 Mar; 21(7):. PubMed ID: 32235439
[TBL] [Abstract][Full Text] [Related]
14. [Not Available].
Pagès C; Baroudjian B; Lebbé C
Bull Cancer; 2016 Nov; 103 Suppl 1():S132-S137. PubMed ID: 28057176
[TBL] [Abstract][Full Text] [Related]
15. Systemic treatments for metastatic cutaneous melanoma.
Pasquali S; Hadjinicolaou AV; Chiarion Sileni V; Rossi CR; Mocellin S
Cochrane Database Syst Rev; 2018 Feb; 2(2):CD011123. PubMed ID: 29405038
[TBL] [Abstract][Full Text] [Related]
16. Programmed Cell Death Protein Ligand 2 Is a Potential Biomarker That Predicts the Efficacy of Immunotherapy.
Wang A; Chu H; Jin Z; Jia Q; Zhu B
Dis Markers; 2021; 2021():9453692. PubMed ID: 34754345
[TBL] [Abstract][Full Text] [Related]
17. Tumor Immune Microenvironment Characterization Identifies Prognosis and Immunotherapy-Related Gene Signatures in Melanoma.
Liu D; Yang X; Wu X
Front Immunol; 2021; 12():663495. PubMed ID: 34025664
[TBL] [Abstract][Full Text] [Related]
18. Future perspectives in melanoma research: meeting report from the "Melanoma Bridge": Napoli, December 3rd-6th 2014.
Ascierto PA; Atkins M; Bifulco C; Botti G; Cochran A; Davies M; Demaria S; Dummer R; Ferrone S; Formenti S; Gajewski TF; Garbe C; Khleif S; Kiessling R; Lo R; Lorigan P; Arthur GM; Masucci G; Melero I; Mihm M; Palmieri G; Parmiani G; Puzanov I; Romero P; Schilling B; Seliger B; Stroncek D; Taube J; Tomei S; Zarour HM; Testori A; Wang E; Galon J; Ciliberto G; Mozzillo N; Marincola FM; Thurin M
J Transl Med; 2015 Nov; 13():374. PubMed ID: 26619946
[TBL] [Abstract][Full Text] [Related]
19. Tumor matrix remodeling and novel immunotherapies: the promise of matrix-derived immune biomarkers.
Mushtaq MU; Papadas A; Pagenkopf A; Flietner E; Morrow Z; Chaudhary SG; Asimakopoulos F
J Immunother Cancer; 2018 Jul; 6(1):65. PubMed ID: 29970158
[TBL] [Abstract][Full Text] [Related]
20. [Tissue biomarkers of response to anti-PD-1 immunotherapies in melanoma].
Adam J; Tomasic G; Robert C
Ann Pathol; 2017 Feb; 37(1):55-60. PubMed ID: 28111041
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
